Back to Newsroom

Catalyst Pharmaceuticals Completes Enrollment in Second Phase 3 Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic Syndrome

CORAL GABLES, Fla., Oct. 31, 2017 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the completion of enrollment in the LMS-003 Phase 3 trial evaluating Firdapse® (amifampridine phosphate) in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).